La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Sotera Health a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Sotera Health..

Sotera Health (NASDAQ:SHC) Azioni, Catena delle Opzioni

Sotera Health

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.

Sotera Health Co

Sharp Corp

Shi Corp

SEARCH MINERALS INC ORD by Search Minerals, Inc.

Search Minerals Inc

Soho House & Co Inc. Class A Common Stock

Soho House & Co Inc

SHARECARE INC CL A

SHARECARE INC RED WT EXP

News

SBGI

Sinclair And IIT Bombay Partner On Wireless Broadcast-to-Everything (B2X) Research; MoU To Enhance ATSC 3.0 Standard For Mobile, TV, And IoT Applications With 5G Integration And Low-Latency Datacasting

Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed's existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility.

Buybacks

Chemed Authorizes An Additional $300M For Stock Repurchase

Keefe, Bruyette &amp; Woods analyst Timothy Switzer reiterates NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) with a Market Perform and raises the price target from $13 to $15.

Price Target

Reiteration

Analyst Ratings

NEWT

Keefe, Bruyette & Woods Reiterates Market Perform on NewtekOne, Raises Price Target to $15

HC Wainwright &amp; Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) with a Buy and maintains $5 price target.

PRLD

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target

Shares of Airbnb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) tumbled in early trading on Friday, after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41825994/airbnb-stock-down-on-q3-earnings-building-on-robust-momentum-in-september-we-are-off-to-a-great-sta">downbeat third-quarter results</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Piper Sandler On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcbc1f558000155e858/thomas-champion">Analyst Thomas Champion</a> maintained a Neutral, while raising the price target from $125 to $145.
Airbnb reported third-quarter gross bookings and revenues of $20.1 billion and $3.7 billion, up 10% year-on-year and 9% year-on-year, respective, with both coming in higher than estimates, Champion said in a note. The company's results were "solid" and reflected "firming demand trends," he added.
Airbnb repurchased shares worth around $1.1 billion, higher than its average of $500 million in the first and second quarters, with remaining authorization of $4.2 billion, the analyst stated. Management indicated expenses in marketing and investment in new businesses "to reignite growth," he further wrote.
JPMorgan On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591479b8290fa7000138e4b4/doug-anmuth">Analyst Doug Anmuth</a> reiterated a Neutral rating, while lifting the price target from $121 to $142.
Despite the challenges faced in the second quarter, "broad-based strength in demand trends &amp; a normalization of booking lead times" generated growth in GBV (gross booking value) through the third quarter and into the fourth, Anmuth said.
The company's fourth-quarter guidance of N&amp;E (Nights &amp; Experiences) acceleration "reflects continued healthy travel demand trends, a normalized booking window relative to last quarter, and success across core optimizations and market expansion, despite tougher comps," the analyst wrote. With investments in marketing and product development expected to continue through 2025, Airbnb's margins could remain under pressure in the near term, he added.
Goldman Sachs On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33195064ed000173030b/eric-sheridan">Analyst Eric Sheridan</a> reiterated a Sell, raising the price target from $103 to $107.
Airbnb indicated demand strength into the fourth quarter across its core and expansion markets, which build on "demand accelerating every month since July," Sheridan said. The company's revenue guidance for the fourth quarter reflects "an acceleration in room nights/experiences booked compared to Q3," he stated.
"Lead times have now normalized globally exiting Q3 and mgmt. pointed to factors like the Olympics contributing to softness in long lead time bookings at the start of the quarter," the analyst wrote. He added, however, that investments in long-term platform expansion efforts "created upward pressure on expenses (esp. marketing and product) into Q4," resulting in uncertainty around the company's margins in 2025.
Wedbush On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58459503ee7bf6000154d075/scott-devitt">Analyst Scott Devitt</a> maintained an Outperform rating, while upping the price target from $135 to $155.
While reporting better-than-expected third-quarter results, Airbnb provided "a mixed outlook," Devitt said. The company's 2024 adjusted EBITDA margin guidance of approximately 35.5% implies fourth-quarter margins of about 27%, below the consensus of 29.7%, he added.
Margins will come under pressure as the company "continues to invest in marketing as well as product teams in advance of upcoming launches next year," the analyst stated. There are several potential catalysts in 2025, including mix shift to higher growth expansion markets, "take rate expansion supported by monetization improvements and new host/guest services, and growth beyond the core," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Truist Securities On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59e8ba80efacff0001417468/patrick-scholes">Analyst Patrick Scholes</a> reiterated a Hold rating and price target of $124.
Better-than-expected margins drove Airbnb's EBITDA to $100 million, higher than Street estimates, Scholes said. He added, however, that the situation is likely to reverse in the fourth quarter, as the guidance implies margins around 300 basis points (bps) lower than consensus.
Nonetheless, the third-quarter results and fourth-quarter earnings guidance indicate full-year adjusted EBITDA above the consensus, the analyst stated. Booking lead times normalized as the year progressed and the company did not mention signs of slowing demand in the U.S. like it had during its second-quarter release, he said.
Benchmark On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d3cdb7b85e930001808a59/daniel-kurnos">Analyst Daniel Kurnos</a> reaffirmed a Buy rating and price target of $155.
Airbnb delivered "a solid, all-around quarter," with every metric modestly beating consensus expectations, Kurnos said. The company's third-quarter "bodes well for our previously non-consensus, almost double-digit nights and experiences call for 4Q," he added.
The analyst stated, however, that Airbnb remains in "the sentiment penalty box after a couple of tough prints," which is why its stock declined when the fourth-quarter margin guidance came in below Street expectations. 
The company's plans to launch several new "billion dollar standalone" businesses, investments in non-core market growth, and commentary on adding hotels on the platform "probably spooked the cash flow crowd a bit as well," he further wrote.
Needham On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587635595064ed000140010c/scott-berg">Analyst Bernie McTernan</a> maintained a Hold rating on the stock.
Nights booked grew by 8.5% year-on-year in the third quarter, slowing by 20 bps sequentially, McTernan said. Despite a slow start to the quarter, "demand grew each month of 3Q, accelerating every month and into October," he added.
"The company attributed this to more normalized lead times, app bookings growth (58% of nights booked vs 53% YoY), and new first time bookers," the analyst wrote. Comps will get easier in September and October relative to November and December, and year-on-year trends are likely to stabilize, he stated.
Oppenheimer On Airbnb
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ef86f00bd9910001e5afe6/jed-kelly">Analyst Jed Kelly</a> reaffirmed a Perform rating on the stock.
Although Airbnb's nights-booked decelerated sequentially by around 20 bps in the third quarter, this was better than Street&#8217;s expectations of 150 bps, Kelly said. The better-than-anticipated performance was due to strength in the Latin America and Asia Pacific regions, he added.
The company guided to fourth-quarter revenue of $2.39-$2.44 billion, which implies an acceleration in nights booked and bookings growth of 10%-12% year-on-year, the analyst stated. The full-year EBITDA margin guide of 35.5% implies "4Q EBITDA $642M, 26.6% margins contracting 670bps-y/y driven by S&amp;M/ Product deleverage and lower take-rates from gift cards," he further wrote.
ABNB Price Action: Shares of Airbnb were down 8% to $135.56 at the time of publication on Friday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/24/10/41233338/i-make-180-000-a-month-off-properties-i-dont-even-own-airbnb-arbitrage-is-a-golden-goose-for-many-yo">&#8216;I Make $180,000 A Month off Properties I Don&#8217;t Even Own&#8217; – Airbnb Arbitrage Is A Golden Goose For Many Young Hustlers</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings Beats

Travel

Movers

Trading Ideas

Real Estate

ABNB

Airbnb's Margins Under Pressure Despite Q3 Beat, Analysts Caution

JP Morgan analyst Paul Coster maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and lowers the price target from $20 to $15.

ARRY

JP Morgan Maintains Overweight on Array Technologies, Lowers Price Target to $15

Legal

Global

ASML

ASML, Tokyo Electron Queried By U.S. Lawmakers On Sales To China

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Outperform and raises the price target from $30 to $33.

Keefe, Bruyette & Woods Maintains Outperform on Marex Group, Raises Price Target to $33

JP Morgan analyst Reginald Smith maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $47 to $56.

AFRM

JP Morgan Maintains Overweight on Affirm Holdings, Raises Price Target to $56

HC Wainwright &amp; Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) with a Buy and maintains $7 price target.

PBYI

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target

JP Morgan analyst Tien-Tsin Huang maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Neutral and raises the price target from $28 to $36.

TOST

JP Morgan Maintains Neutral on Toast, Raises Price Target to $36

Guidance

Fluor During Conference Call, Said Company 'Four Quarters Behind' Its Prior 2026 EBITDA Target

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) with a Outperform and raises the price target from $380 to $400.

CPAY

Keefe, Bruyette & Woods Maintains Outperform on Corpay, Raises Price Target to $400

JP Morgan analyst Rahul Krotthapalli maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Overweight and raises the price target from $80 to $90.

PLNT

JP Morgan Maintains Overweight on Planet Fitness, Raises Price Target to $90

WIIM

RIGL

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

JP Morgan analyst Doug Anmuth maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and raises the price target from $121 to $142.

JP Morgan Maintains Neutral on Airbnb, Raises Price Target to $142

HC Wainwright &amp; Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) with a Buy and maintains $10 price target.

RPTX

HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target

<a href="https://www.bnnbloomberg.ca/business/company-news/2024/11/08/boeing-ceo-says-furloughed-workers-will-be-paid-for-lost-time/#:~:text=%E2%80%9CAs%20we%20navigated%20through%20the,first%20weeks%20of%20his%20tenure.">https://www.bnnbloomberg.ca/business/company-news/2024/11/08/boeing-ceo-says-furloughed-workers-will-be-paid-for-lost-time/#:~:text=%E2%80%9CAs%20we%20navigated%20through%20the,first%20weeks%20of%20his%20tenure.</a>
Boeing Co. Chief Executive Officer Kelly Ortberg moved to patch up relations with workers after a bruising seven-week strike, saying the company would pay employees who were put on mandatory leave during the disruption at its Seattle manufacturing hub.
"As we navigated through the work stoppage, we asked many of you to take a furlough to support our cash conservation efforts," Ortberg said in a memo to staff. "We want to acknowledge your support by returning your lost pay."
Ortberg made the temporary cuts as cash concerns mounted in the first weeks of his tenure. The strike by Seattle-area factory workers paralyzed plane output already suppressed by a months-long crisis tied to quality issues in its planemaking operations.&nbsp;
The gesture of goodwill to furloughed staff signals the CEO's attention has shifted toward mending operations as he tries to get aircraft output back on track. The walkout is now settled, with union members receiving 38% wage increases and a $12,000 signing bonus. Ortberg has raised more than $20 billion to ease the company's cash crunch.&nbsp;
In the memo, Ortberg said the company will press ahead with job cuts to align with "our financial reality," a sign that the pain is far from over. Structural changes "are important to our competitiveness," he said. The company said last month that it would eliminate the equivalent of about 17,000 positions to help preserve funds.
Boeing has initiated a range of cost cuts as it grapples with dwindling reserves and low output, including hiring freezes and cutbacks in corporate travel. The company has said it expects to continue burning cash in the first half of next year as it works to restore output.&nbsp;
Ortberg has also said he plans to review non-core assets with a view to refocusing on the commercial planemaking business.&nbsp;

Management

Reported Earlier, "Boeing CEO Says Furloughed Workers Will Be Paid for Lost Time" - BNN Bloomberg

Crypto analyst Benjamin Cowen suggests that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dominance might continue climbing, even as it hits his long-standing 60% target, following the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path">Fed's recent 25 basis point interest rate cut</a>.
What Happened: In an update on his YouTube <a href="https://youtu.be/NPu6mfY_Pz8?si=35Qnt5mVElqCe9nx">channel</a>, Cowen analyzed the Federal Reserve's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path">decision to reduce rates</a> to lowest level since February 2023 and maintain quantitative tightening by continuing to reduce its holdings in Treasury securities and mortgage-backed securities.
He highlighted that Bitcoin's dominance has typically peaked (60%) only after quantitative easing (QE) starts. This time, he sees two possible scenarios: Bitcoin dominance could begin a topping process, or it might overshoot its peak before settling back.
He also emphasized monitoring Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) performance against Bitcoin, as it plays a key role in dominance trends. Cowen recommended dollar-cost averaging in altcoins as the market heads into the post-halving phase.
Quoting the Federal Reserve&#8217;s press release, Cowen highlighted that the committee plans to "continue reducing its Holdings of Treasury Securities and agency debt and agency mortgage-backed Securities." He stressed the potential influence of this decision on the crypto market.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a>
Why It Matters: Despite his cautious outlook, Cowen anticipates Bitcoin will adhere to its cyclical behaviour. He warned, however, that a broader market correction could interrupt these patterns, impacting both Bitcoin and altcoins.
The Federal Reserve&#8217;s decision to lower interest rates has slowed the pace of rate cuts compared to September, when policymakers opted for a more substantial 0.5% cut to initiate the easing cycle.
A senior research strategist noted that that the Fed's gradual cuts toward a "neutral" 3% rate could be partly due to Trump's policies, including tariffs, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41824236/feds-interest-rate-cut-pace-expected-to-slow-economists-weigh-trumps-white-house-re">which may have a reflationary effect</a>.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41807557/bitcoin-as-americas-gold-trumps-bitcoin-act-could-reshape-us-reserves-says-coinshares">Bitcoin As America&#8217;s Gold? How Trump&#8217;s Bitcoin Act Could Reshape US Reserves</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Federal Reserve Cuts Interest Rates—Bitcoin Dominance May Rise As A Result

ALVR

AlloVir shares are trading lower. The company announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics.

Sotera Health announces secondary offering of common stock

Sotera Health ( ($SHC) ) has shared an announcement. Following a recent stock sale by certain shareholders, Sotera Health Company's Board of Direct...

Sotera Health Board Changes and Shareholder Stock Sale

RBC Capital analyst Sean Dodge reiterated a Buy rating on Sotera Health (SHC – Research Report) on November 1 and set a price target of $17.00. The...

RBC Capital Sticks to Its Buy Rating for Sotera Health (SHC)

Sotera Health Non-GAAP EPS of $0.17 misses by $0.01, revenue of $285M beats by $6.42M

Sotera Health Company (SHC) Q3 2024 Earnings Call Transcript

Barclays analyst Luke Sergott maintained a Buy rating on Sotera Health (SHC – Research Report) today and set a price target of $18.00. The company'...

Sotera Health (SHC) Gets a Buy from Barclays

Barclays analyst Luke Sergott raised the firm's price target on Sotera Health (SHC) to $18 from $17 and keeps an Overweight rating on the shares. T...

Sotera Health price target raised to $18 from $17 at Barclays

Citi raised the firm's price target on Sotera Health (SHC) to $20 from $18 and keeps a Buy rating on the shares. The firm cites the "solid" Q3 resu...

Sotera Health price target raised to $20 from $18 at Citi

In a report released yesterday, Casey Woodring from J.P. Morgan maintained a Hold rating on Sotera Health (SHC – Research Report), with a price tar...

J.P. Morgan Sticks to Their Hold Rating for Sotera Health (SHC)

Analyst David Windley of Jefferies maintained a Buy rating on Sotera Health (SHC – Research Report), with a price target of $18.00. David Windley h...

Sotera Health's Future Growth Potential and Margin Improvement Lead to Buy Rating with $18 Price Target

Press Releases

SHAREHOLDER ALERT: Morris Kandinov Investigating HRT, CRNC, SHC and INNV; Shareholders are Encouraged to Contact the Firm

Sotera Health Announces First-Quarter 2024 Earnings Release Date

Earnings

Sotera Health Reports First-Quarter 2024 Results

Financing

Sotera Health Announces Closing of $1.5 Billion Term Loan B and $750 Million Senior Secured Note Financings

Sotera Health Announces Second-Quarter 2024 Earnings Release Date

Sotera Health Appoints Christopher Simon to the Board of Directors

Sotera Health Reports Second-Quarter and First-Half 2024 Results

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Dates for Third-Quarter 2024 Earnings Release and November 2024 Investor Day

Sotera Health Reports Third-Quarter and Year-to-Date 2024 Results

CRNC

INNV

Agilent Technologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Sotera Health

Sotera Health (SHC) Opzioni

Sotera Health (NASDAQ:SHC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO